Articles and Videos
Neurodegenerative Disease Studies of Cannabinoid Analogs
InMed's Senior VP, Preclinical Research and Development, Dr. Eric Hsu, shares results from early neurodegenerative disease studies demonstrating how specific cannabinoids induced neuroprotective effects and...
Source: Tribe Public
Why explore cannabinoids as potential therapeutic targets for neurodegenerative diseases?
In this video, Eric A. Adams explains how the body’s endocannabinoid system has natural cannabinoid receptors throughout the body that interact with cannabinoids and are...
Source: The Dales Report
The Dales Report: InMed Pharmaceuticals Clinical Trial Program Moving Forward In 2023
InMed's CEO, Eric A. Adams, joins The Dales Report webcast to talk about the 2023 plans for the company's rare cannabinoid programs in epidermolysis bullosa...
Source: The Dales Report
The Dales Report: InMed Focused On Clinical Trial Success In 2023
The Dales Report's Shadd Dales interviews InMed CEO, Eric A. Adams, to talk about the company's upcoming pharmaceutical development plans for 2023. Eric speaks about...
Source: The Dales Report
Tribe Webinar: Exploring the Neuroprotective Qualities of Rare Cannabinoids
InMed's President and CEO, Eric A. Adams, and Senior VP, Preclinical Research and Development, Dr. Eric Hsu, talks about "Exploring the Neuroprotective Qualities of Rare...
Source: Tribe Public
Epidermolysis Bullosa News: INM-755 Found Safe in 5 Adults With EB, Trial Opens to Adolescents
Epidermolysis Bullosa News writes about InMed's Phase 2 clinical trial of INM-755 cannabinol cream, an investigational new treatment for epidermolysis bullosa. Excerpt: INM-755 was found to...
